Virginia Retirement Systems Et Al Nektar Therapeutics Transaction History

Virginia Retirement Systems Et Al

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$10.83 - $18.41 $174,363 - $296,401	-16,100 Closed	0 $0
Q3 2021 Oct 21, 2021	SELL	$13.07 - $18.84 $5,228 - $7,536	-400 Reduced 2.42%	16,100 $289,000
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $62,776 - $77,520	3,800 Added 29.92%	16,500 $283,000
Q1 2021 Apr 30, 2021	BUY	$16.56 - $25.46 $11,592 - $17,822	700 Added 5.83%	12,700 $254,000
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $37,848 - $45,672	-2,400 Reduced 16.67%	12,000 $204,000
Q3 2020 Nov 12, 2020	SELL	$16.59 - $24.79 $117,789 - $176,009	-7,100 Reduced 33.02%	14,400 $239,000
Q2 2020 Aug 12, 2020	BUY	$16.86 - $23.44 $13,488 - $18,752	800 Added 3.86%	21,500 $498,000
Q1 2020 May 12, 2020	SELL	$14.47 - $27.96 $189,557 - $366,276	-13,100 Reduced 38.76%	20,700 $369,000
Q4 2019 Jan 27, 2020	BUY	$15.87 - $23.12 $536,406 - $781,456	33,800 New	33,800 $730,000
Q4 2018 Feb 07, 2019	SELL	$30.43 - $56.65 $368,203 - $685,465	-12,100 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$46.25 - $104.45 $559,625 - $1.26 Million	12,100 New	12,100 $591,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $178M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.